Part of The Mesothelioma Center. Contact Us
Mesothelioma-Line.com.
Journal Articles on Mesothelioma: Cancer Information for Patients and Families

Archive for the 'Imatinib Mesylate (Gleevec/Glivec)' Category

Imatinib Mesylate (Gleevec/Glivec) news feed.

June 6th, 2008. Long-term mortality from pleural and peritoneal cancer after exposure to asbestos: Possible role of asbestos clearance

The risk for pleural cancer, rather than showing an indefinite increase, might reach a plateau when a sufficiently long time has elapsed since exposure. The different trends for pleural and peritoneal cancer might be related to clearance of the asbestos from the workers' lungs.
Posted in Causation, Determining Efficacy, Diagnosis & Differentiation, Epidemiological, Full Archive, Imatinib Mesylate (Gleevec/Glivec), Intraperitoneal Chemotherapy, Occupational Asbestos Exposure, Oxaliplatin (Eloxatin), PET Scan, Pleural, Pleural Catheters, Proton Beam Therapy, Staging, Symptoms & Symptom Management, Treatment, Type of Assessment:, melphalan, paclitaxel | No Comments »

October 3rd, 2007. Phase I and Pharmacokinetic Study of Imatinib Mesylate (Gleevec) and Gemcitabine in Patients with Refractory Solid Tumors

Conclusion: The addition of intermittently dosed IM to GEM at low to full dose was associated with broad antitumor activity and little increase in toxicity.
Posted in Chemotherapy, Determining Efficacy, Full Archive, Gemcitabine (Gemzar), Imatinib Mesylate (Gleevec/Glivec), Treatment, Type of Assessment: | No Comments »

June 13th, 2005. Limited efficacy of imatinib mesylate in malignant mesothelioma: A phase II trial

Side effects of the medication were mild and included edema, nausea, constipation and diarrhea. We conclude that further investigation with monotherapy imatinib in mesothelioma is not warranted.
Posted in Chemotherapy, Full Archive, Imatinib Mesylate (Gleevec/Glivec), Treatment, Type of Assessment: | No Comments »
Goldberg, Persky & White, P.C. Mesothelioma Lawyers